The Z (Glu342Lys) variant of a 1 -antitrypsin is common in populations of North European descent. The mutation causes individual a 1 -antitrypsin molecules to assemble into polymer chains in the endoplasmic reticulum of hepatocytes. Z homozygotes (PiZZ) have circulating levels of a 1 -antitrypsin w15% of normal and are predisposed to hepatic cirrhosis and severe, early-onset emphysema. The risk of clinically significant disease associated with the heterozygote PiMZ state is minimal. We describe a case phenotyped as PiZZ during family screening, but with surprisingly preserved circulating a 1 -antitrypsin levels. Genotyping revealed compound heterozygosity for the Z mutation and a novel, "pseudo-Z" mutation. Biochemical and ion-mobility mass spectrometry characterisation of pseudo-Z a 1 -antitrypsin showed that it readily populated a polymerogenic intermediate state under physiological conditions.
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Cell biological studies of a series of a 1 -antitrypsin variants indicated these effects involved disruption of a hydrogen bond stabilising the F-helix-linker region of the protein structure. These data strongly support the hypothesis that stability of this region co-regulates formation of the polymerogenic intermediate. Whilst the intermediate form of pseudo-Z a 1 -antitrypsin is more stable than that of the true Z variant, the resultant polymers all share a characteristic neoepitope. Pseudo-Z a 1 -antitrypsin is thus a useful model for in vitro screening of potential lead compounds to bind the polymerogenic intermediate state, improving the ability to develop novel therapies to treat a 1 -antitrypsin deficiency. Our data predict that the likelihood of severe disease in the PiZ/Pseudo-Z compound heterozygote state will be increased relative to the PiMZ state, but far lower than for PiZZ individuals. Polymerisation causes circulating deficiency of a 1 -antitrypsin while predisposing to hepatic cirrhosis and severe, early-onset emphysema. Targeting the conformational transitions underlying polymerisation via ligand binding and stabilisation of the physiological native state is therefore a goal of drug design in a 1 -antitrypsin deficiency. To complement previous structure-led approaches we have developed NMR spectroscopy and nanospray mass spectrometry as mediumthroughput screening tools for such ligands. The coupling of these techniques combines highly sensitive detection of ligand binding with assessment of binding sites, stoichiometry, cooperativity and binding constants. We have used the TTAI peptide, developed within an existing programme of drug design, as a test case. The data demonstrate highly co-operative, slow, tight binding of two copies of the peptide in adjacent parts of the a 1 -antitrypsin molecule. TTAI peptide binding is shown to induce widespread conformational change all over the molecule with the exception of b-sheet C. These data prove the utility of NMR spectroscopy and nanospray mass spectrometry in characterising ligand binding whilst providing a highly detailed template for use in specific screening for TTAI peptide-mimetic compounds. We have identified a subgroup of patients with a reduced FEV 1 but normal gas transfer determined by the lower limit of normal (LLN), that is, with standardised residual (SR) value <À1.645. The current abstract reports the progression of these physiological measures with time in this subgroup. Methods 533 patients with A1AD were studied of whom 43 had isolated FEV 1 abnormality at baseline and also had $3 years of complete annual follow-up data. These patients were followed for a mean of 5.9 (2.2 SD) years. Of these, 22 remained with isolated FEV 1 abnormality (Group A) whereas 21 had developed evidence of a reduced K,co deficiency (Group B). Group A and B data at baseline and at last follow-up were compareddsee Abstract S64 
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USE OF NMR SPECTROSCOPY AND NANOSPRAY MASS SPECTROMETRY TO CHARACTERISE BINDING OF LEAD COMPOUNDS FOR DRUG DESIGN IN a1-ANTITRYPSIN
